PharmaCyte Biotech Inc (PMCB)

[Mens et Manus]

Very interesting article on BMS and Celg treating Pancreatic cancer. Curious if Pharmacyte would also team with Bristol as well.

https://www.yahoo.com/

Bristol-Myers Squibb's Opdivo May Change How We Treat Pancreatic Cancer

Last year, Bristol-Myers Squibb and Celgene announced that they'll study a one-two punch combination approach in pancreatic cancer that combines Opdivo with Celgene's Abraxane, a chemotherapy drug.

Abraxane is already approved for use in metastatic pancreatic cancer patients. In clinical trials, patients receiving Abraxane and the commonly used cancer drug gemcitabine lived 1.8 months longer than patients taking gemcitabine alone.

Bristol-Myers Squibb and Celgene hope that adding Opdivo to that regimen could add additional months to survival, and the two companies are currently recruiting patients for a phase 1 safety study that will run until mid-2017. Although the primary goal of this study is to make sure that the combination is safe, the trial will also evaluate progression-free survival and overall survival.